THRB and thyroid gland carcinoma: Kim et al. showed 90% reduction in thyroid hormone receptor β (THRB) mRNA expression in differentiated thyroid carcinomas, in particularly those with advanced histologic features suggesting an inverse correlation, which when treated with demethylating agents 5′-aza-2′ deoxynucleotide and/or zebularine induced 5.6 fold increase in re-expression of the THRB gene and concurrent inhibition of tumour growth by inhibition of cell proliferation and migration through the suppression of β-catenin signalling pathway [133].